AWM
VRDN icon

Avior Wealth Management’s Viridian Therapeutics VRDN Stock Holding History

Avior Wealth Management’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-8
Closed -$140 – 3704
2024
Q1 		$140 Buy
+8
New +$155 ﹤0.01% 3037

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Avior Wealth Management's VRDN Position: Q2 2024 in Review

Avior Wealth Management sold out of Viridian Therapeutics (VRDN) in Q2 2024, closing a stake of 8 shares — an estimated $140 sold.

Avior Wealth Management first reported a position in VRDN in Q1 2024 and held it in 1 quarter. The position peaked at $140 in Q1 2024. 138 funds tracked by Wall St. Rank hold VRDN as of Q2 2024.

  • Avior Wealth Management reported no remaining Viridian Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Avior Wealth Management sold 8 Viridian Therapeutics shares in Q2 2024, an estimated $140.
  • Avior Wealth Management first reported a position in Viridian Therapeutics in Q1 2024 and held it in 1 quarter.
  • Avior Wealth Management's Viridian Therapeutics position peaked at $140 in Q1 2024.
  • 138 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2024.

Based on Avior Wealth Management's 13F filing for Q2 2024, filed 13 Aug 2024.